Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304851 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Hui-Han Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United State…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Infliximab. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the impact of the entry of biosimilars on the pricing of eight biologic products in 57 countries and regions.
Methods
We utilized an interrupted time series design and IQVIA MIDAS® data to analyze the annual sales data of eight biologic products (adalimumab, bevacizumab, epoetin, etanercept, filgrastim, infliximab, pegfilgrastim, and trastuzumab) across 57 countries and regions from January 1, 2012, to December 31, 2019. We examined the immediate and long-term changes in biologics ex-manufacturer pricing following the entry of biosimilars to the market.
Results
Following the entry of biosimilars, the average price per dose of biologic product was immediately reduced by $438 for trastuzumab, $112 for infliximab, and $110 for bevacizumab. The persistent effect of biosimilars’ market entry led to further reductions in price per dose every year: by $49 for adalimumab, $290 for filgrastim, $21 for infliximab, and $189 for trastuzumab. Similarly, we analyzed the impact of biosimilars on four biologics’ prices in the US, where the prices of three biologics significantly decreased every year, with filgrastim, pegfilgrastim, and infliximab decreasing by $955, $753, and $104, respectively.
Conclusions
The introduction of biosimilars has significantly reduced the prices of biologics both globally and in the US. These findings not only demonstrate the economic benefits of increasing biosimilar utilization, but also emphasize the importance of biosimilars in controlling healthcare costs. Policies should aim to expand the availability of biosimilars to counteract the exponential growth of medical spending caused by the use of biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States of America.
- Department of Maternal and Child Health, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States of America.
ORCID-Profile: Hui-Han Chen
Zitieren
APA
Chen, H. H., Yemeke, T., & Ozawa, S. (2024). Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19. PLOS ONE. https://doi.org/10.1371/journal.pone.0304851
Vancouver
Chen HH, Yemeke T, Ozawa S. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19. PLOS ONE. 2024. doi:10.1371/journal.pone.0304851
BibTeX
@article{Chen2024,
author = {Chen, Hui-Han and Yemeke, Tatenda and Ozawa, Sachiko},
title = {Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304851}
}
EUVIMED